(BPMC) - Earnings & Price History

BPMC: - 71.52, $2.78B, 5.10 (7.68%)

Sector: Healthcare - Industry: Biotechnology

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that can become abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyr

Past BPMC reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-09-0.7639.3236.2337.1636.2539.782.57%5.81%8.53%758.74K
2016-11-10-0.7934.7733.1934.5733.1935.24.16%0.58%4.76%423.70K
2016-08-09-0.7323.5723.7623.9922.423.990.97%▲-1.75%-0.80%194.67K
2016-05-10-0.715.2415.3615.514.9215.710.91%-1.68%-0.78%145.49K
2016-03-11-0.53

Login | Register
Friday Sep 21, 2018   EST
Enter a Ticker:

Economic Calendar

PMI Composite FLASH 9:45 AM ET Baker-Hughes Rig Count 1:00 PM ET 

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades